objective response rate
Showing 1 - 8 of 8
Advanced Breast Cancer, Objective Response Rate, Trastuzumab Emtansine Trial in Nanjing (Trastuzumab Emtansine (T-DM1))
Recruiting
- Advanced Breast Cancer
- +2 more
- Trastuzumab Emtansine (T-DM1)
-
Nanjing, Jiangsu, ChinaJiangSu Province Hospital/ The First Affiliated Hospital of Nanj
Nov 5, 2023
Objective Response Rate Trial in Wuhan (GM-CSF)
Recruiting
- Objective Response Rate
-
Wuhan, Hubei, ChinaRenmin Hospital of Wuhan University
Feb 25, 2023
Fasting Mimicking Diet, HER2-negative Breast Cancer, Hormone Receptor-positive Breast Cancer Trial in Netherlands (Fasting
Not yet recruiting
- Fasting Mimicking Diet
- +5 more
- Fasting Mimicking diet program
-
Alkmaar, Netherlands
- +14 more
Aug 15, 2022
Recurrent Cervical Carcinoma, Metastatic Cervical Carcinoma, Persistent Cervical Carcinoma Trial in Beijing (Tislelizumab plus
Recruiting
- Recurrent Cervical Carcinoma
- +9 more
- Tislelizumab plus radiotherapy
-
Beijing, Beijing, ChinaLei Li
Apr 1, 2022
Objective Response Rate Trial in Jinan (albumin-bound paclitaxe combined with bevacizumab biosimilar)
Recruiting
- Objective Response Rate
- albumin-bound paclitaxe combined with bevacizumab biosimilar
-
Jinan, Shandong, ChinaQilu Hospital of Shandong University
Oct 7, 2021
Objective Response Rate Trial in Hangzhou (CD19 PD-1/CD28 CAR-T Plus Low Dose Decitabine)
Recruiting
- Objective Response Rate
- CD19 PD-1/CD28 CAR-T Plus Low Dose Decitabine
-
Hangzhou, Zhejiang, China2nd Affiliated Hospital, School of Medicine, Zhejiang University
Jun 5, 2021
Recurrent Cervical Carcinoma, Radiotherapy, Epidermal Growth Factor Receptor Trial in Beijing (Combination of nimotuzumab and
Recruiting
- Recurrent Cervical Carcinoma
- +6 more
- Combination of nimotuzumab and radiotherapy
-
Beijing, Beijing, ChinaLei Li
Dec 18, 2020
Chemo, Anti-pd-1 Antibody, Cervical Neuroendocrine Carcinoma Trial in Beijing (Drug therapy)
Recruiting
- Chemotherapy
- +6 more
- Drug therapy
-
Beijing, Beijing, ChinaLei Li
Nov 15, 2020